KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Liabilities and Shareholders Equity (2016 - 2026)

Gsk has reported Liabilities and Shareholders Equity over the past 18 years, most recently at $84.8 billion for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 10.86% year-over-year to $84.8 billion; the TTM value through Mar 2026 reached $327.9 billion, up 8.75%, while the annual FY2025 figure was $81.3 billion, 6.52% up from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $84.8 billion at Gsk, up from $81.3 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $112.1 billion in Q2 2022 and troughed at $60.4 billion in Q1 2022.
  • A 5-year average of $77.3 billion and a median of $75.4 billion in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 43.89% in 2022 and later rose 17.89% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $70.5 billion in 2022, then increased by 3.81% to $73.2 billion in 2023, then increased by 4.21% to $76.3 billion in 2024, then rose by 6.52% to $81.3 billion in 2025, then increased by 4.26% to $84.8 billion in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for GSK at $84.8 billion in Q1 2026, $81.3 billion in Q4 2025, and $82.8 billion in Q3 2025.